Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Tarceva Price Will Be Bounded By Iressa And Gleevec, OSI Says

This article was originally published in The Pink Sheet Daily

  • News
  • Adam Eckstein

Executive Summary

The dose and pharmacokinetic profile of Tarceva allow for premium pricing over AstraZeneca's Iressa, OSI CEO Colin Goddard says. Approval of Tarceva for the treatment of non-small cell lung cancer possible by late January.

You may also be interested in...



Genentech/OSI Raise Tarceva Price 15% In Wake Of Iressa Failure

Genentech/OSI Raise Tarceva Price 15% In Wake Of Iressa Failure

Tarceva Sales Effort Will Be Led By Genentech; OSI To Provide 25% Of Reps

An amendment to the companies' 2001 Tarceva development and marketing agreement clarifies responsibilities for each party upon FDA approval of the oncologic. OSI will be responsible for manufacturing commercial supply; the company plans to outsource production to third parties.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS060273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By